Loratadine for the Prevention of G-CSF-related Bone Pain

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions

Stem Cell Transplant Complications

Interventions

DRUG

Loratadine

Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.

DRUG

Placebo

Placebo sugar pill

Trial Locations (1)

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors

lead

AHS Cancer Control Alberta

OTHER